SEC Contract Filing

Filing Date: 2016-11-08

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d231852dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>KARYOPHARM THERAPEUTICS INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CONTROLLED EQUITY OFFERING<SUP STYLE="font-size:85%; vertical-align:top">SM</SUP></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT NO.&nbsp;1 TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SALES AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">November&nbsp;7, 2016 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cantor
Fitzgerald&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">499 Park Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY
10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Reference is
made to the Sales Agreement, dated December&nbsp;7, 2015, including the Schedules thereto (the &#147;<U>Sales Agreement</U>&#148;), between Cantor Fitzgerald&nbsp;&amp; Co. (&#147;<U>CF&amp;Co</U>&#148;) and Karyopharm Therapeutics Inc., a Delaware
corporation (the &#147;<U>Company</U>&#148;), pursuant to which the Company agreed to sell through CF&amp;Co, as sales agent, shares of common stock, par value $0.0001 per share, of the Company. All capitalized terms used in this Amendment
No.&nbsp;1 to Sales Agreement between CF&amp;Co and the Company (this &#147;<U>Amendment</U>&#148;) and not otherwise defined herein shall have the respective meanings assigned to such terms in the Sales Agreement. CF&amp;Co and the Company agree as
follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. <U>Amendments to Sales Agreement</U>. The Sales Agreement is amended as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. The first paragraph of Section&nbsp;1 of the Sales Agreement is hereby amended and restated as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company agrees that, from time to time on or after November&nbsp;7, 2016 and during the term of this Agreement, on the terms and subject
to the conditions set forth herein, it may issue and sell through the Agent, shares of common stock (the &#147;<B><U>Placement Shares</U></B>&#148;) of the Company, par value $0.0001 per share (the &#147;<B><U>Common Stock</U></B>&#148;), having an
aggregate offering price of up to $50,000,000;<I>&nbsp;provided</I>,<I>&nbsp;however</I>, that in no event shall the Company issue or sell through the Agent such number or dollar amount of Placement Shares that would (a)&nbsp;exceed the number or
dollar amount of shares of Common Stock registered on the effective Registration Statement (defined below) pursuant to which the offering is being made, (b)&nbsp;exceed the number of authorized but unissued shares of Common Stock (less shares of
Common Stock issuable upon exercise, conversion or exchange of any outstanding securities of the Company or otherwise reserved from the Company&#146;s authorized capital stock), (c)&nbsp;exceed the number or dollar amount of shares of Common Stock
permitted to be sold under Form S-3 (including General Instruction I.B.6 thereof, if applicable) or (d)&nbsp;exceed the number or dollar amount of shares of Common Stock for which the Company has filed a Prospectus Supplement (defined below) (the
lesser of (a), (b), (c)&nbsp;and (d), the &#147;<B><U>Maximum Amount</U></B>&#148;).&nbsp;Such amount of Placement Shares available for offer and sale are in addition to any offers and sales of Placement Shares made prior to the date hereof under
the Prospectus Supplement filed by the Company on May&nbsp;19, 2016. Notwithstanding anything to the contrary contained herein, the parties hereto agree that compliance with the limitations set forth in this<U>&nbsp;Section&nbsp;1</U>&nbsp;on the
amount of Placement Shares </P>

<p Style='page-break-before:always'>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
issued and sold under this Agreement shall be the sole responsibility of the Company and that Agent shall have no obligation in connection with such compliance. The issuance and sale of Placement
Shares through Agent will be effected pursuant to the Registration Statement (as defined below) filed by the Company which registration statement initially became effective upon filing with the Securities and Exchange Commission (the
&#147;<B><U>Commission</U></B>&#148;) on January&nbsp;5, 2015, which was subsequently amended on March&nbsp;15, 2016 and May&nbsp;17, 2016, and such post-effective amendment filed on May&nbsp;17, 2016 was&nbsp;declared&nbsp;effective by the
Commission on&nbsp;May&nbsp;17, 2016, although nothing in this Agreement shall be construed as requiring the Company to use the Registration Statement to issue Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; text-indent:4%; font-size:10pt; font-family:Times New Roman">